AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ABBV?
Source: Fool
- Stable Dividend Growth: AbbVie has raised its quarterly dividend every year since becoming independent in 2013, with the latest dividend at $1.73 per share, or $6.92 annually, demonstrating strong cash flow and shareholder returns despite challenges from Humira's patent expiration.
- Sales Driven by New Drugs: Sales from Skyrizi and Rinvoq are projected to reach $50 billion by 2030, having generated $31 billion in 2025, effectively countering the decline in Humira sales and ensuring future profitability for AbbVie.
- Neuroscience Portfolio Growth: AbbVie's neuroscience products, including Vraylar and Botox Therapeutic, have seen low-teens percentage year-over-year growth, supporting the company's financial health despite declines in other areas like oncology and aesthetics treatments.
- Future Dividend Potential: With earnings expected to rise by 45.4% in 2026 and 10.8% in 2027, AbbVie is positioned for larger dividend increases in the future, and while it is still years away from becoming a Dividend King, its growth potential remains significant.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 206.690
Low
223.00
Averages
252.00
High
289.00
Current: 206.690
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie and Roche Launch Medicines on TrumpRx Platform
- Discounted Drug Offerings: AbbVie's arthritis drug Humira will be available on the TrumpRx platform at an 86% discount, reflecting a drug pricing deal with the Trump administration that is expected to significantly reduce patient costs.
- New Drug Additions: Roche's Genentech unit is also launching its flu medication Xofluza on TrumpRx for $50, down from a list price of approximately $168, further enhancing the platform's appeal to consumers.
- Increase in Product Range: The total number of drugs available on TrumpRx has grown from about 40 in February to 61, demonstrating the platform's success in attracting pharmaceutical companies and expanding drug options for consumers.
- Intensifying Market Competition: With Amgen also expanding its offerings on TrumpRx to include Enbrel and Otezla, competition in the market is intensifying, prompting pharmaceutical companies to continuously adjust their strategies to address pricing pressures and consumer demands.
See More
AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges
- Stable Dividend Growth: AbbVie has raised its quarterly dividend every year since becoming independent in 2013, with the latest dividend at $1.73 per share, or $6.92 annually, demonstrating strong cash flow and shareholder returns despite challenges from Humira's patent expiration.
- Sales Driven by New Drugs: Sales from Skyrizi and Rinvoq are projected to reach $50 billion by 2030, having generated $31 billion in 2025, effectively countering the decline in Humira sales and ensuring future profitability for AbbVie.
- Neuroscience Portfolio Growth: AbbVie's neuroscience products, including Vraylar and Botox Therapeutic, have seen low-teens percentage year-over-year growth, supporting the company's financial health despite declines in other areas like oncology and aesthetics treatments.
- Future Dividend Potential: With earnings expected to rise by 45.4% in 2026 and 10.8% in 2027, AbbVie is positioned for larger dividend increases in the future, and while it is still years away from becoming a Dividend King, its growth potential remains significant.
See More
AbbVie Successfully Navigates Patent Cliff, Sustains Dividend Growth
- Patent Cliff Navigation: AbbVie has successfully navigated the challenge of Humira's patent expiration by launching new drugs like Skyrizi and Rinvoq, ensuring over a decade of dividend growth, which demonstrates its resilience and adaptability in the pharmaceutical industry.
- Sales Growth Expectations: Forecasts indicate that sales of Skyrizi and Rinvoq will increase from $31 billion in 2025 to $50 billion by 2030, further driving overall revenue growth and enhancing investor confidence in AbbVie's future prospects.
- Sustained Dividend Growth: AbbVie recently raised its quarterly dividend by 5.5% to $1.73 per share, resulting in an annualized dividend of $6.92, with a current yield of approximately 3.2%, providing stable returns for long-term investors.
- Optimistic Earnings Outlook: With projected earnings growth of 45.4% in 2026 and 10.8% in 2027, AbbVie is well-positioned for larger dividend increases in the future, further enhancing the attractiveness of its stock for investors.
See More
AbbVie Raises Dividend Annually for Over a Decade
- Dividend Growth: AbbVie has raised its quarterly dividend every year since becoming independent in 2013, with the latest dividend at $1.73 per share, translating to an annual payout of $6.92, and a current yield of approximately 3.2%, demonstrating strong shareholder return capabilities despite challenges from Humira's patent expiration.
- New Drug Momentum: The launches of Skyrizi and Rinvoq are projected to boost sales from $31 billion in 2025 to around $50 billion by 2030, helping AbbVie offset declining Humira sales and solidifying its market position in immunology.
- Diverse Product Portfolio: AbbVie's neuroscience portfolio, including Vraylar, Botox Therapeutic, and Ubrelvy, has seen year-over-year growth in the low-teens percentage range, further supporting overall sales growth despite declines in other drugs like Imbruvica and Juvederm.
- Future Outlook: With earnings expected to rise by 45.4% in 2026 and 10.8% in 2027, AbbVie is well-positioned for larger dividend increases in the future; although the current P/E ratio is around 17, this valuation may be justified given the company's strong growth prospects.
See More
U.S. Economic Outlook Dims Amid Iran Tensions
- Market Weakness: The S&P 500 index showed significant weakness as President Trump's deadline for Iran approached, with most of the session in the red, reflecting investor concerns over economic prospects amid declining consumer confidence and rising inflation.
- Retail Sector Decline: Walmart's 3.3% drop indicates that even budget-conscious consumers may cut back on spending during an economic downturn, suggesting a deteriorating overall consumer health that could have long-term implications for the retail sector.
- Cruise Industry Struggles: Shares of Royal Caribbean, Norwegian Cruise Line, and Carnival fell nearly 3%, 3.3%, and 2.96% respectively, indicating a potential decline in consumer demand for travel post-pandemic, which raises further concerns about economic recovery.
- Pharmaceutical Stocks Underperform: Merck, Pfizer, and AbbVie saw declines of 1.3%, 2.6%, and 0.2%, respectively, highlighting inflationary pressures and the dual challenges of economic slowdown and rising costs faced by the pharmaceutical industry.
See More
AbbVie Forecasts Significant Earnings Growth Amid Challenges
- Earnings Growth Forecast: AbbVie projects its adjusted diluted earnings per share (EPS) to range between $13.96 and $14.16 in 2026, a significant increase from $10.00 in 2025, indicating the company's ability to achieve profitability growth despite challenges from the loss of Humira's patent.
- Strong New Drug Performance: The new drugs Skyrizi and Rinvoq are performing exceptionally well, driving revenue diversification; despite the revenue loss from Humira, AbbVie continues to show robust growth momentum, enhancing investor confidence.
- Increased Dividend Returns: AbbVie offers a dividend yield of 3.3%, significantly higher than the S&P 500's 1.2%, and has tripled its quarterly payout rate over the past decade, demonstrating a strong commitment to shareholder returns.
- Market Valuation Analysis: While AbbVie has a high price-to-earnings ratio of 88, its actual trading multiple based on future earnings expectations is only 14, indicating that the company remains attractive in terms of long-term growth potential and stable dividends.
See More
AbbVie and Roche Launch Medicines on TrumpRx Platform
- Discounted Drug Offerings: AbbVie's arthritis drug Humira will be available on the TrumpRx platform at an 86% discount, reflecting a drug pricing deal with the Trump administration that is expected to significantly reduce patient costs.
- New Drug Additions: Roche's Genentech unit is also launching its flu medication Xofluza on TrumpRx for $50, down from a list price of approximately $168, further enhancing the platform's appeal to consumers.
- Increase in Product Range: The total number of drugs available on TrumpRx has grown from about 40 in February to 61, demonstrating the platform's success in attracting pharmaceutical companies and expanding drug options for consumers.
- Intensifying Market Competition: With Amgen also expanding its offerings on TrumpRx to include Enbrel and Otezla, competition in the market is intensifying, prompting pharmaceutical companies to continuously adjust their strategies to address pricing pressures and consumer demands.
See More
AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges
- Stable Dividend Growth: AbbVie has raised its quarterly dividend every year since becoming independent in 2013, with the latest dividend at $1.73 per share, or $6.92 annually, demonstrating strong cash flow and shareholder returns despite challenges from Humira's patent expiration.
- Sales Driven by New Drugs: Sales from Skyrizi and Rinvoq are projected to reach $50 billion by 2030, having generated $31 billion in 2025, effectively countering the decline in Humira sales and ensuring future profitability for AbbVie.
- Neuroscience Portfolio Growth: AbbVie's neuroscience products, including Vraylar and Botox Therapeutic, have seen low-teens percentage year-over-year growth, supporting the company's financial health despite declines in other areas like oncology and aesthetics treatments.
- Future Dividend Potential: With earnings expected to rise by 45.4% in 2026 and 10.8% in 2027, AbbVie is positioned for larger dividend increases in the future, and while it is still years away from becoming a Dividend King, its growth potential remains significant.
See More
AbbVie Successfully Navigates Patent Cliff, Sustains Dividend Growth
- Patent Cliff Navigation: AbbVie has successfully navigated the challenge of Humira's patent expiration by launching new drugs like Skyrizi and Rinvoq, ensuring over a decade of dividend growth, which demonstrates its resilience and adaptability in the pharmaceutical industry.
- Sales Growth Expectations: Forecasts indicate that sales of Skyrizi and Rinvoq will increase from $31 billion in 2025 to $50 billion by 2030, further driving overall revenue growth and enhancing investor confidence in AbbVie's future prospects.
- Sustained Dividend Growth: AbbVie recently raised its quarterly dividend by 5.5% to $1.73 per share, resulting in an annualized dividend of $6.92, with a current yield of approximately 3.2%, providing stable returns for long-term investors.
- Optimistic Earnings Outlook: With projected earnings growth of 45.4% in 2026 and 10.8% in 2027, AbbVie is well-positioned for larger dividend increases in the future, further enhancing the attractiveness of its stock for investors.
See More
AbbVie Raises Dividend Annually for Over a Decade
- Dividend Growth: AbbVie has raised its quarterly dividend every year since becoming independent in 2013, with the latest dividend at $1.73 per share, translating to an annual payout of $6.92, and a current yield of approximately 3.2%, demonstrating strong shareholder return capabilities despite challenges from Humira's patent expiration.
- New Drug Momentum: The launches of Skyrizi and Rinvoq are projected to boost sales from $31 billion in 2025 to around $50 billion by 2030, helping AbbVie offset declining Humira sales and solidifying its market position in immunology.
- Diverse Product Portfolio: AbbVie's neuroscience portfolio, including Vraylar, Botox Therapeutic, and Ubrelvy, has seen year-over-year growth in the low-teens percentage range, further supporting overall sales growth despite declines in other drugs like Imbruvica and Juvederm.
- Future Outlook: With earnings expected to rise by 45.4% in 2026 and 10.8% in 2027, AbbVie is well-positioned for larger dividend increases in the future; although the current P/E ratio is around 17, this valuation may be justified given the company's strong growth prospects.
See More
U.S. Economic Outlook Dims Amid Iran Tensions
- Market Weakness: The S&P 500 index showed significant weakness as President Trump's deadline for Iran approached, with most of the session in the red, reflecting investor concerns over economic prospects amid declining consumer confidence and rising inflation.
- Retail Sector Decline: Walmart's 3.3% drop indicates that even budget-conscious consumers may cut back on spending during an economic downturn, suggesting a deteriorating overall consumer health that could have long-term implications for the retail sector.
- Cruise Industry Struggles: Shares of Royal Caribbean, Norwegian Cruise Line, and Carnival fell nearly 3%, 3.3%, and 2.96% respectively, indicating a potential decline in consumer demand for travel post-pandemic, which raises further concerns about economic recovery.
- Pharmaceutical Stocks Underperform: Merck, Pfizer, and AbbVie saw declines of 1.3%, 2.6%, and 0.2%, respectively, highlighting inflationary pressures and the dual challenges of economic slowdown and rising costs faced by the pharmaceutical industry.
See More
AbbVie Forecasts Significant Earnings Growth Amid Challenges
- Earnings Growth Forecast: AbbVie projects its adjusted diluted earnings per share (EPS) to range between $13.96 and $14.16 in 2026, a significant increase from $10.00 in 2025, indicating the company's ability to achieve profitability growth despite challenges from the loss of Humira's patent.
- Strong New Drug Performance: The new drugs Skyrizi and Rinvoq are performing exceptionally well, driving revenue diversification; despite the revenue loss from Humira, AbbVie continues to show robust growth momentum, enhancing investor confidence.
- Increased Dividend Returns: AbbVie offers a dividend yield of 3.3%, significantly higher than the S&P 500's 1.2%, and has tripled its quarterly payout rate over the past decade, demonstrating a strong commitment to shareholder returns.
- Market Valuation Analysis: While AbbVie has a high price-to-earnings ratio of 88, its actual trading multiple based on future earnings expectations is only 14, indicating that the company remains attractive in terms of long-term growth potential and stable dividends.
See More
